Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DM79KLR)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Nafadotride; 149649-22-9; (+-)-nafadotride; N-[(1-BUTYL-2-PYRROLIDINYL)METHYL]-4-CYANO-1-METHOXY-2-NAPHTHALENECARBOXAMIDE; N-[(1-butylpyrrolidin-2-yl)methyl]-4-cyano-1-methoxynaphthalene-2-carboxamide; CHEMBL286252; CHEBI:64191; A1-01951; SMR000466292; AC1MPBUT; GTPL44; MLS000758952; MLS001424218; SCHEMBL635866; DTXSID1042603; CTK8H0240; MolPort-023-276-076; HMS3394A15; HMS3267P15; HMS2232B11; HMS2052A15; HMS3370D02; BCP27779; BDBM50133923; AKOS024257976; TRA0072321; CCG-101119; NC00369; SAM001247092; CPD000466292; LS-186981; LS-187623
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||
|
||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
